Rani Therapeutics (RANI) Expected to Post Quarterly Earnings on Thursday

Rani Therapeutics (NASDAQ:RANI) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.05) per share and revenue of $1.28 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Rani Therapeutics (NASDAQ:RANI) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $1.71 million for the quarter, compared to analyst estimates of $0.93 million. On average, analysts expect Rani Therapeutics to post ($0.17) EPS for the current fiscal year and ($0.20) EPS for the next fiscal year.

Rani Therapeutics Stock Down 6.5%

RANI stock opened at $0.55 on Tuesday. Rani Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.63. The stock’s 50 day moving average is $0.76 and its two-hundred day moving average is $0.93. The company has a market capitalization of $76.92 million, a PE ratio of -2.04 and a beta of 0.69.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on RANI. Weiss Ratings raised shares of Rani Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Chardan Capital restated a “buy” rating on shares of Rani Therapeutics in a research note on Thursday, October 22nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Rani Therapeutics in a report on Tuesday, October 6th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Rani Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.33.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc is a clinical-stage biotherapeutics company developing technology designed to deliver biologic medicines orally. Its proprietary RaniPill platform is an ingestible robotic capsule intended to transport biologic drugs through the stomach and release them into the small intestine, where they can be absorbed into the bloodstream. The approach is intended to address the limitations of many biologic therapies, which are commonly administered by injection or infusion.

The company is advancing the RaniPill platform for potential use with a range of large-molecule medicines, including peptides, proteins and antibodies.